TP53 and breast carcinoma: In fact, a combined index of microenvironment heterogeneity and DNA alteration—namely, TP53 mutation or copy number loss of 4p14 or 5q13—was able to improve the accuracy of prognosis in grade 3 breast cancer patients in our cohorts further, identifying subgroups of patients with disease-specific survival rates of 35%, 9%, and 32%, respectively.